Effect of corticosteroid treatment and enucleation on the visual prognosis of sympathetic ophthalmia.
A retrospective clinicopathologic study, conducted to determine the course of disease in 30 cases of sympathetic ophthalmia with clinical follow-up of at least six months (average, 12.7 years), showed that 21 of 30 patients retained visual acuities of 20/50 or better in the sympathizing eye. The severity of inflammation graded histologically in the exciting eye did not correlate with the clinical course of final visual acuity in the sympathizing eye. Enucleation of the exciting eye within two weeks of the onset of symptoms was associated with a relatively benign clinical course (P = .008). Corticosteroid treatment in patients who underwent enucleation more than two weeks after the onset of symptoms was associated with a good visual outcome (P = .009). Early enucleation of a blind exciting eye and corticosteroid treatment appear to be important variables that influence the visual prognosis in the sympathizing eye.
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009879:Ophthalmia, Sympathetic / Q000503:physiopathology / Q000628:therapy*; D013508:Ophthalmologic Surgical Procedures; D011379:Prognosis; D012189:Retrospective Studies; D014605:Uveitis / Q000188:drug therapy / Q000601:surgery*; D014792:Visual Acuity
D000305:Adrenal Cortex Hormones